Stroma

Akoya Biosciences to Showcase New Spatial Biology 2.0 Solutions and Spatial Phenotyping Data at SITC 2023

Retrieved on: 
Tuesday, October 31, 2023
Biomarker, Society for Immunotherapy of Cancer, Head, Organization, Entrepreneurship, Research, Poster, HNSCC, SITC, Tissue, Immunotherapy, Proteome, Annual general meeting, University, Tumor microenvironment, Society, Patient, Spatial organization, Translation, Cultured pearl, Fine chemical, Medical imaging, Communications satellite, Akoya, Stroma, Neoplasm

MARLBOROUGH, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences Inc., (Nasdaq: AKYA) The Spatial Biology Company®, today announced that it will be showcasing its latest Spatial Biology 2.0 solutions and ultrahigh-plex (100+ protein biomarkers) spatial phenotyping data at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, being held in San Diego, California, November 1-5, 2023.

Key Points: 
  • MARLBOROUGH, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences Inc., (Nasdaq: AKYA) The Spatial Biology Company®, today announced that it will be showcasing its latest Spatial Biology 2.0 solutions and ultrahigh-plex (100+ protein biomarkers) spatial phenotyping data at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, being held in San Diego, California, November 1-5, 2023.
  • At booth #719, Akoya Biosciences will highlight its new PhenoCycler®-Fusion 2.0 and PhenoImager® HT 2.0 platforms, which offer significant advancements in speed and scale for spatial biology research.
  • PhenoCycler-Fusion 2.0: Features multi-slide automation, enabling researchers to generate ultrahigh-plex spatial phenotyping data for larger and more complex samples at unprecedented speed.
  • “We’re excited to be at SITC where we will highlight these innovations and share an extensive array of new spatial phenotyping data.

Alabama Futures Fund Invests in Stroma Vision, Inc.

Retrieved on: 
Thursday, July 21, 2022
Investment, Environment, GLOBE, Intelligence, Injury, Fund, CEO, PPE, Compliance, Fatigue, Redhawk, Workforce, Accident, Safety, The Chartered Institute of Ergonomics and Human Factors, Machine learning, Â, Workplace, AFF, LLC, Stroma

BIRMINGHAM, Ala., July 21, 2022 (GLOBE NEWSWIRE) -- Alabama Futures Fund (AFF or the Fund) recently placed an investment in Stroma Vision, Inc. (Stroma Vision or Stroma).

Key Points: 
  • BIRMINGHAM, Ala., July 21, 2022 (GLOBE NEWSWIRE) -- Alabama Futures Fund (AFF or the Fund) recently placed an investment in Stroma Vision, Inc. (Stroma Vision or Stroma).
  • This represents the fifteenth investment from AFF since the Fund launched in Q4 of 2018.
  • As with previous AFF investments in companies located outside the State of Alabama, Stroma Vision will move its headquarters to Alabama.
  • Redhawk Advisory, LLC (Redhawk) serves as the investment manager of AFF and advised AFF on the Stroma Vision investment.

RoosterBio Inc. Announces Winners of 2020 hMSC Development Grants

Retrieved on: 
Thursday, March 11, 2021
Biotechnology, Bioprocess, Stromal cell, Stroma

FREDERICK, Md., March 11, 2021 /PRNewswire-PRWeb/ -- RoosterBio, a leading supplier of human mesenchymal stem/stromal cell (hMSC) working cell banks and hMSC bioprocess systems, announced the 2020 Winners of our RoosterBio Development Award.

Key Points: 
  • FREDERICK, Md., March 11, 2021 /PRNewswire-PRWeb/ -- RoosterBio, a leading supplier of human mesenchymal stem/stromal cell (hMSC) working cell banks and hMSC bioprocess systems, announced the 2020 Winners of our RoosterBio Development Award.
  • Each awardee will receive up to $12,000 in requested RoosterBio's hMSC and bioprocess media products in support of their respective proposed projects.
  • These systems have built-in design to streamline not just product development, but also to accelerate manufacturing processes for projects en route to early-stage clinical development.
  • RoosterBio has simplified and standardized how living cells are purchased, expanded, and used in development, leading to marked time and costs savings for customers.

Cell-Easy Announces the Completion of a Financing Round to Accelerate Its Growth Trajectory in the Cell Therapy Sector, With Merieux Equity Partners as Lead Investor and Reference Shareholder.

Retrieved on: 
Tuesday, December 8, 2020
Biotechnology, Health, Science, Research, Clinical trials, Branches of biology, Stem cells, Corporate finance, Equity securities, Stroma, Mesenchymal stem cell, Venture capital, Cell-Easy -, Merieux Equity Partners -

Many research studies have also highlighted that fat tissue is an abundant source of cells having therapeutic properties, the mesenchymal stromal cells.

Key Points: 
  • Many research studies have also highlighted that fat tissue is an abundant source of cells having therapeutic properties, the mesenchymal stromal cells.
  • Merieux Equity Partners is a management company registered with the Autorit des Marchs Financiers (AMF) since June 2018 that is dedicated to Venture Capital and Growth Equity & Buy-Out.
  • Merieux Equity Partners currently operates with an international team of 20 employees and business partners based in Europe and North America.
  • Merieux Equity Partners actively supports entrepreneurs and industrial companies whose products and services bring differentiated and innovative solutions in the healthcare and nutrition sectors.

Remestemcel-L Reduces Inflammatory Biomarkers Predictive of High Mortality in Acute Graft Versus Host Disease

Retrieved on: 
Monday, December 7, 2020
Branches of biology, Biology, Stem cells, Life sciences, Regenerative biomedicine, Mesoblast, Biotechnology, Cell therapy, Mesenchymal stem cell, Stroma, Bone marrow, Prochymal

Remestemcel-L is an investigational therapy comprising culture-expanded mesenchymal stromal cells derived from the bone marrow of an unrelated donor.

Key Points: 
  • Remestemcel-L is an investigational therapy comprising culture-expanded mesenchymal stromal cells derived from the bone marrow of an unrelated donor.
  • Mesoblast Limited (Nasdaq:MESO; ASX:MSB) is a world leader in developing allogeneic (off-the-shelf) cellular medicines.
  • The Company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of commercial products and late-stage product candidates.
  • Mesoblast has a strong and extensive global intellectual property portfolio with protection extending through to at least 2040 in all major markets.

Avalon GloboCare Announces Mesenchymal Stromal Cell Therapeutic Platform for COVID-19 and Acute Graft Versus Host Disease (aGVHD)

Retrieved on: 
Thursday, September 3, 2020
Branches of biology, Medical specialties, Stem cells, Biology, Mesenchymal stem cell, Graft-versus-host disease, Stromal cell, Stroma, Hematopoietic stem cell transplantation, Bone marrow, Cytokine, Prochymal

FREEHOLD, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today announced the launch of its new allogeneic mesenchymal stromal cell (MSC) therapeutic platform.

Key Points: 
  • FREEHOLD, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today announced the launch of its new allogeneic mesenchymal stromal cell (MSC) therapeutic platform.
  • Avalon plans to develop the MSC platform as a potential therapy for COVID-19, the disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and for bone marrow transplant related complications of acute graft versus host disease (aGVHD).
  • Mesenchymal stromal cells are typically isolated from the bone marrow, umbilical cord blood, fat tissue and other tissue types.
  • MSCs have the ability to suppress T-cell proliferation, cytokine secretion and regulate the balance of antibody-based and cell-based immune responses.

Cell-Easy Becomes the First Private Pharmaceutical Company in France Allowed to Manufacture Stem Cells

Retrieved on: 
Tuesday, June 9, 2020
Research, Other Health, Pharmaceutical, Mental health, Other Manufacturing, Genetics, Clinical trials, Science, Biotechnology, Medical Supplies, Health, Other Science, Manufacturing, Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Cell biology, Mesenchymal stem cell, Cell therapy, Stromal cell, Stroma, Stem-cell therapy, Induced stem cells

The start-up has now signed a first partnership with the University Hospital Center in Toulouse and will be producing Mesenchymal stem cells (or stromal cells) sourced from qualified fat tissue in accordance with good manufacturing practices.

Key Points: 
  • The start-up has now signed a first partnership with the University Hospital Center in Toulouse and will be producing Mesenchymal stem cells (or stromal cells) sourced from qualified fat tissue in accordance with good manufacturing practices.
  • Our ambition is to industrialize our proprietary stem cell manufacturing process to make Cell Therapy accessible to the largest number possible of patients.
  • This authorization makes Cell-Easy the only private pharmaceutical organization able to manufacture stem cells in France on an industrial scale.
  • Cell-Easy will now be able to manufacture stem cells batches for industrial partners and is one of the worlds precursors in cell therapy.

RoosterBio Radically Simplifies Online Ordering Experience

Retrieved on: 
Tuesday, January 21, 2020
Articles, Life sciences, Biomanufacturing, Biopharmaceuticals, Biotechnology, Food industry, Pharmaceutical industry, Industries, Stromal cell, Stroma

FREDERICK, Md., Jan. 21, 2020 /PRNewswire-PRWeb/ --RoosterBio, a leading supplier of innovative human mesenchymal stem/stromal cell (hMSC) biomanufacturing systems, has made its online buying experience more efficient with the launch of the newly redesigned roosterbio.com website.

Key Points: 
  • FREDERICK, Md., Jan. 21, 2020 /PRNewswire-PRWeb/ --RoosterBio, a leading supplier of innovative human mesenchymal stem/stromal cell (hMSC) biomanufacturing systems, has made its online buying experience more efficient with the launch of the newly redesigned roosterbio.com website.
  • The website offers a radically simplified, user-friendly experience with improved navigation and functionality, while allowing its global customers to gain deeper knowledge of RoosterBio's standardized regenerative medicine products and biomanufacturing solutions.
  • Specifically, we wanted to improve the informed online buying experience to grow our relationships with customers," said RoosterBio CEO Margot Connor.
  • RoosterBio has simplified and standardized how living cells are purchased, expanded, and used in development, leading to marked time and costs savings for customers.

RoosterBio Expands Facility for Second Time in 2019

Retrieved on: 
Wednesday, December 18, 2019
Branches of biology, Cell biology, Connective tissue cells, Biology, Stromal cell, Stroma, Vesicle, Stem cells

FREDERICK, Md., Dec. 18, 2019 /PRNewswire-PRWeb/ --RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cell (hMSC) working cell banks and hMSC bioprocess systems, announces today an expansion of its facility in Frederick, Maryland for the second time in 2019.

Key Points: 
  • FREDERICK, Md., Dec. 18, 2019 /PRNewswire-PRWeb/ --RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cell (hMSC) working cell banks and hMSC bioprocess systems, announces today an expansion of its facility in Frederick, Maryland for the second time in 2019.
  • By strengthening its cell manufacturing solution portfolio and presence in the Asia Pacific and Europe, RoosterBio is giving more people around the world the ability to advance regenerative medicine cures.
  • RoosterBio announced the first expansion of its facility earlier this year which served as a catalyst for its strategic international growth initiatives.
  • RoosterBio will also be launching a cGMP version of its extracellular vesicle production tools in early 2020.

RoosterBio Cell Manufacturing Experts and Biomanufacturing Leaders to Discuss hMSC BioProcess Solutions at Biotech Week Boston

Retrieved on: 
Tuesday, September 3, 2019
Articles, Life sciences, Biotechnology, Biopharmaceuticals, Biology, Biomanufacturing, Food industry, Pharmaceutical industry, Bioprocess, Stroma

FREDERICK, Md., Sept. 3, 2019 /PRNewswire-PRWeb/ --RoosterBio, Inc, a leading supplier of innovative human mesenchymal stem/stromal cell (hMSC) biomanufacturing systems, will present and exhibit during Biotech Week Boston at the BioProcess International (BPI) Conference & Exhibition and Cell & Gene Therapy BioProcessing & Commercialization Meeting September 9-12, 2019 in Boston, MA.

Key Points: 
  • FREDERICK, Md., Sept. 3, 2019 /PRNewswire-PRWeb/ --RoosterBio, Inc, a leading supplier of innovative human mesenchymal stem/stromal cell (hMSC) biomanufacturing systems, will present and exhibit during Biotech Week Boston at the BioProcess International (BPI) Conference & Exhibition and Cell & Gene Therapy BioProcessing & Commercialization Meeting September 9-12, 2019 in Boston, MA.
  • RoosterBio cell manufacturing experts will share strategies and solutions for rapidly streamlining the path to clinical manufacturing.
  • This pre-conference workshop is under the Tissue track and Next Generation Tools for Manufacturing Regenerative Medicine Products at Scale.
  • RoosterBio, Inc. is a privately held cell manufacturing platform technology company focused on accelerating the development of a sustainable regenerative medicine industry, one customer at a time.